Thomas Miller/Linkedin
Jun 16, 2025, 15:00
Thomas Miller: Unlocking Smarter BCL-2 Inhibitor Therapies After EHA 2025
Thomas Miller, Principal Investigator at Institut Paoli-Calmettes, shared a post on LinkedIn:
“Unlocking Smarter BCL-2 Inhibitor Therapies After EHA2025
Excellent final day at EHA2025. Institut Paoli-Calmettes was particularly engaged by the dedicated session on BCL-2 inhibitor therapies, highlighted by Sylvain Garciaz’s insightful presentation on inherent and acquired resistance mechanisms.
This critical discussion sparks a vital question: How can we develop smarter strategies to utilize BCL-2 inhibitors, circumvent multi-drug resistance, and unlock new combination opportunities, especially for the elderly patient population?
At Institut Paoli-Calmettes, we are committed to exploring these avenues, pushing the boundaries of research to enhance treatment efficacy and improve patient outcomes.
Let’s continue this crucial conversation and collaborate on innovative solutions!”
Find more posts featuring EHA 2025.
-
Nov 16, 2025, 19:46Ayodeji Olayanju: Academics Blood Matter Too!
-
Nov 16, 2025, 19:30Thomas Reiser Congratulates Saskia Middeldorp on Delivering the 2025 Sol Sherry Distinguished Lecture in Thrombosis
-
Nov 15, 2025, 15:47Shannon Farmer: Congratulations to Susan Goobie and Colleagues on Publication of Their Important Study
-
Nov 15, 2025, 15:46Fotios Barkas: Explore the Latest Articles From the Journal of Atherosclerosis Prevention and Treatment!
-
Nov 15, 2025, 15:45Ludovic Helfgott: Researchers Have Analysed Novo Nordisk Product Data in Obesity and Cardiovascular Disease
-
Nov 15, 2025, 15:42Haroun Gajraj Thanks Enric Roche for Demonstrating the Piston Effect
-
Nov 15, 2025, 15:41Thrombectomy Rates Rise 700% Nationwide
-
Nov 15, 2025, 15:41Emmanuel J. Favaloro: Transitioning Patients from DOACs to Heparin
-
Nov 15, 2025, 15:40Bruno Lima: I Owe a Lot of My Career to Dr. Brad Maron